Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 97 to 102 of 102 entries
Sorted by: Best Match Show Resources per page
Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy.

Nature cancer

Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, Verma A, Goel S, Halmos B.
PMID: 34661163
Nat Cancer. 2021 Apr;2(4):392-399. doi: 10.1038/s43018-021-00191-y. Epub 2021 Mar 22.

Patients with cancer have been identified in several studies to be at high risk of developing severe COVID-19; however, rates of SARS-CoV-2 IgG seroconversion and its association with cancer types and anti-cancer therapy remain obscure. We conducted a retrospective...

Cite
Thakkar A, Pradhan K, Jindal S, et al. Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy. Nat Cancer. 2021;2(4):392-399doi: 10.1038/s43018-021-00191-y.
Thakkar, A., Pradhan, K., Jindal, S., Cui, Z., Rockwell, B., Shah, A. P., Packer, S., Sica, R. A., Sparano, J., Goldstein, D. Y., Verma, A., Goel, S., & Halmos, B. (2021). Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy. Nature cancer, 2(4), 392-399. https://doi.org/10.1038/s43018-021-00191-y
Thakkar, Astha, et al. "Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy." Nature cancer vol. 2,4 (2021): 392-399. doi: https://doi.org/10.1038/s43018-021-00191-y
Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, Verma A, Goel S, Halmos B. Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy. Nat Cancer. 2021 Apr;2(4):392-399. doi: 10.1038/s43018-021-00191-y. Epub 2021 Mar 22. PMID: 34661163; PMCID: PMC8519533.
Copy Download .nbib Format: NLM
Deconstructing Racial and Ethnic Disparities in Breast Cancer.

JAMA oncology

Sparano JA, Brawley OW.
PMID: 33475709
JAMA Oncol. 2021 Mar 01;7(3):355-356. doi: 10.1001/jamaoncol.2020.7113.

No abstract available.

Cite
Sparano JA, Brawley OW. Deconstructing Racial and Ethnic Disparities in Breast Cancer. JAMA Oncol. 2021;7(3):355-356doi: 10.1001/jamaoncol.2020.7113.
Sparano, J. A., & Brawley, O. W. (2021). Deconstructing Racial and Ethnic Disparities in Breast Cancer. JAMA oncology, 7(3), 355-356. https://doi.org/10.1001/jamaoncol.2020.7113
Sparano, Joseph A, and Brawley, Otis W. "Deconstructing Racial and Ethnic Disparities in Breast Cancer." JAMA oncology vol. 7,3 (2021): 355-356. doi: https://doi.org/10.1001/jamaoncol.2020.7113
Sparano JA, Brawley OW. Deconstructing Racial and Ethnic Disparities in Breast Cancer. JAMA Oncol. 2021 Mar 01;7(3):355-356. doi: 10.1001/jamaoncol.2020.7113. PMID: 33475709.
Copy Download .nbib Format: NLM
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Expert review of hematology

Efficace F, Vignetti M, Sparano F, Scalzulli E, Breccia M.
PMID: 33554672
Expert Rev Hematol. 2021 Mar;14(3):293-302. doi: 10.1080/17474086.2021.1886918. Epub 2021 Mar 09.

No abstract available.

Cite
Efficace F, Vignetti M, Sparano F, et al. Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Expert Rev Hematol. 2021;14(3):293-302doi: 10.1080/17474086.2021.1886918.
Efficace, F., Vignetti, M., Sparano, F., Scalzulli, E., & Breccia, M. (2021). Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Expert review of hematology, 14(3), 293-302. https://doi.org/10.1080/17474086.2021.1886918
Efficace, Fabio, et al. "Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors." Expert review of hematology vol. 14,3 (2021): 293-302. doi: https://doi.org/10.1080/17474086.2021.1886918
Efficace F, Vignetti M, Sparano F, Scalzulli E, Breccia M. Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Expert Rev Hematol. 2021 Mar;14(3):293-302. doi: 10.1080/17474086.2021.1886918. Epub 2021 Mar 09. PMID: 33554672.
Copy Download .nbib Format: NLM
Reply to K. Ando et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S.
PMID: 33793318
J Clin Oncol. 2021 Jun 10;39(17):1947-1948. doi: 10.1200/JCO.21.00424. Epub 2021 Apr 01.

No abstract available.

Cite
Sparano JA, Crager MR, Tang G, et al. Reply to K. Ando et al. J Clin Oncol. 2021;39(17):1947-1948doi: 10.1200/JCO.21.00424.
Sparano, J. A., Crager, M. R., Tang, G., Gray, R. J., Stemmer, S. M., & Shak, S. (2021). Reply to K. Ando et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(17), 1947-1948. https://doi.org/10.1200/JCO.21.00424
Sparano, Joseph A, et al. "Reply to K. Ando et al." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,17 (2021): 1947-1948. doi: https://doi.org/10.1200/JCO.21.00424
Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S. Reply to K. Ando et al. J Clin Oncol. 2021 Jun 10;39(17):1947-1948. doi: 10.1200/JCO.21.00424. Epub 2021 Apr 01. PMID: 33793318; PMCID: PMC8260921.
Copy Download .nbib Format: NLM
Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4).

Thyroid : official journal of the American Thyroid Association

Forleo R, Grani G, Alfò M, Zilioli V, Giubbini R, Zatelli MC, Gagliardi I, Piovesan A, Ragni A, Morelli S, Puxeddu E, Pagano L, Deandrea M, Ceresini G, Torlontano M, Puligheddu B, Antonelli A, Centanni M, Fugazzola L, Spiazzi G, Monti S, Rossetto R, Monzani F, Tallini G, Crescenzi A, Sparano C, Bruno R, Repaci A, Tumino D, Pezzullo L, Lombardi CP, Ferraro Petrillo U, Filetti S, Durante C, Castagna MG.
PMID: 34541894
Thyroid. 2021 Dec;31(12):1814-1821. doi: 10.1089/thy.2021.0248. Epub 2021 Oct 20.

No abstract available.

Cite
Forleo R, Grani G, Alfò M, et al. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). Thyroid. 2021;31(12):1814-1821doi: 10.1089/thy.2021.0248.
Forleo, R., Grani, G., Alfò, M., Zilioli, V., Giubbini, R., Zatelli, M. C., Gagliardi, I., Piovesan, A., Ragni, A., Morelli, S., Puxeddu, E., Pagano, L., Deandrea, M., Ceresini, G., Torlontano, M., Puligheddu, B., Antonelli, A., Centanni, M., Fugazzola, L., Spiazzi, G., Monti, S., Rossetto, R., Monzani, F., Tallini, G., Crescenzi, A., Sparano, C., Bruno, R., Repaci, A., Tumino, D., Pezzullo, L., Lombardi, C. P., Ferraro Petrillo, U., Filetti, S., Durante, C., & Castagna, M. G. (2021). Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). Thyroid : official journal of the American Thyroid Association, 31(12), 1814-1821. https://doi.org/10.1089/thy.2021.0248
Forleo, Raffaella, et al. "Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4)." Thyroid : official journal of the American Thyroid Association vol. 31,12 (2021): 1814-1821. doi: https://doi.org/10.1089/thy.2021.0248
Forleo R, Grani G, Alfò M, Zilioli V, Giubbini R, Zatelli MC, Gagliardi I, Piovesan A, Ragni A, Morelli S, Puxeddu E, Pagano L, Deandrea M, Ceresini G, Torlontano M, Puligheddu B, Antonelli A, Centanni M, Fugazzola L, Spiazzi G, Monti S, Rossetto R, Monzani F, Tallini G, Crescenzi A, Sparano C, Bruno R, Repaci A, Tumino D, Pezzullo L, Lombardi CP, Ferraro Petrillo U, Filetti S, Durante C, Castagna MG. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). Thyroid. 2021 Dec;31(12):1814-1821. doi: 10.1089/thy.2021.0248. Epub 2021 Oct 20. PMID: 34541894.
Copy Download .nbib Format: NLM
Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma.

Advances in hematology

Petrich AM, Sparano JA, Parekh S.
PMID: 22570659
Adv Hematol. 2012;2012:403648. doi: 10.1155/2012/403648. Epub 2012 Apr 18.

Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkin's lymphoma that occurs with higher frequency in patients with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy regimens. The addition of the monoclonal antibody...

Cite
Petrich AM, Sparano JA, Parekh S. Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma. Adv Hematol. 2012;2012:403648doi: 10.1155/2012/403648.
Petrich, A. M., Sparano, J. A., & Parekh, S. (2012). Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma. Advances in hematology, 2012403648. https://doi.org/10.1155/2012/403648
Petrich, Adam M, et al. "Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma." Advances in hematology vol. 2012 (2012): 403648. doi: https://doi.org/10.1155/2012/403648
Petrich AM, Sparano JA, Parekh S. Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma. Adv Hematol. 2012;2012:403648. doi: 10.1155/2012/403648. Epub 2012 Apr 18. PMID: 22570659; PMCID: PMC3337598.
Copy Download .nbib Format: NLM
Showing 97 to 102 of 102 entries